Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Additional methodological considerations regarding optimization of the dose of intracerebroventricular streptozotocin A response to: “Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in rats” by Ghosh et al., Metab Brain Dis 2020 July 21 (CROSBI ID 285291)

Prilog u časopisu | ostalo | međunarodna recenzija

Homolak, Jan ; Babić Perhoč, Ana ; Knezović, Ana ; Osmanović Barilar, Jelena ; Šalković-Petrišić, Melita Additional methodological considerations regarding optimization of the dose of intracerebroventricular streptozotocin A response to: “Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairme // Metabolic brain disease, 36 (2020), 6; 97-102. doi: 10.1007/s11011-020-00637-9

Podaci o odgovornosti

Homolak, Jan ; Babić Perhoč, Ana ; Knezović, Ana ; Osmanović Barilar, Jelena ; Šalković-Petrišić, Melita

engleski

Additional methodological considerations regarding optimization of the dose of intracerebroventricular streptozotocin A response to: “Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in rats” by Ghosh et al., Metab Brain Dis 2020 July 21

A recent article by Ghosh et al. entitled "Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in rats" provides an important new set of information on neuroinflammation and cognitive deficit in a rat model of sporadic Alzheimer's disease (sAD) based on intracerebroventricular administration of streptozotocin (STZ-icv) in Charles-Foster rats in the early post-treatment period of 21 days. This comment is supposed to supplement the aforementioned manuscript by providing additional perspective on important factors that should be taken into account in the process of optimization of the streptozotocin (STZ) dose for intracerebroventricular treatment, and provides a brief overview of possible sources of variation of experimental results reported by different groups working with STZ-icv rodent models.

intracerebroventricular ; streptozotocin

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

36 (6)

2020.

97-102

objavljeno

0885-7490

1573-7365

10.1007/s11011-020-00637-9

Trošak objave rada u otvorenom pristupu

APC

Povezanost rada

Temeljne medicinske znanosti

Poveznice
Indeksiranost